Get the Stockscreener App
1.53
2.55%
-0.04
After Hours:
1.53
Inflarx N V stock is traded at $1.53, with a volume of 53,409.
It is down -2.55% in the last 24 hours and down -3.77% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.57
Open:
$1.55
24h Volume:
53,409
Relative Volume:
0.83
Market Cap:
$90.09M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-2.0487
EPS:
-0.7468
Net Cash Flow:
$-41.02M
1W Performance:
+3.38%
1M Performance:
-3.77%
6M Performance:
-0.65%
1Y Performance:
-48.66%
1-Day Range:
$1.52
$1.56
1-Week Range:
$1.46
$1.5874
52-Week Range:
$1.14
$3.0799
Inflarx N V Stock (IFRX) Company Profile
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - MarketBeat
InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat
InflaRx reports promising HS treatment results at EADV Congress - Investing.com
InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks
InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress - StockTitan
InflaRx Announces Participation in September Investor Events - Yahoo Finance UK
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK
InflaRx (NASDAQ:IFRX) Stock Price Up 1.3% - MarketBeat
InflaRx (NASDAQ:IFRX) Shares Up 1.3% - Defense World
InflaRx reports promising data on oral C5aR inhibitor INF904 - Investing.com
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human - EIN News
InflaRx reports promising data on oral C5aR inhibitor INF904 By Investing.com - Investing.com UK
InflaRx presents new preclinical findings for INF904 - TipRanks
InflaRx Presents New Preclinical Findings for INF904 at the - GlobeNewswire
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - StockTitan
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance
InflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in August - MarketBeat
InflaRx Announces Participation in September Investor Events - GlobeNewswire
InflaRx Announces Participation in September Investor Events - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4% - MarketBeat
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx N.V. Reports Mid-Year Financial Results - TipRanks
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
InflaRx reports Q2 EPS (24c), consensus (22c) - TipRanks
InflaRx (IFRX) Set to Announce Earnings on Thursday - Defense World
InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat
InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - GlobeNewswire
InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - StockTitan
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewswire
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases - StockTitan
Vasculitis Treatment Market with Tremendous growth by 2031 – Glaxosmithkline plc, Amneal Pharmaceuticals, Inc., ChemoCentryx, InflaRx N.V – TIMC - TIMC
InflaRx (NASDAQ:IFRX) Short Interest Up 151.1% in June - American Banking and Market News
Short Interest in InflaRx (NASDAQ:IFRX) Expands By 151.1% - MarketBeat
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 151.1% - Defense World
InflaRx Announces $75M Share Sales Agreement - TipRanks
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia
InflaRx (NASDAQ:IFRX) Short Interest Update - MarketBeat
What Kind Of Investors Own Most Of InflaRx N.V. (NASDAQ:IFRX)? - Yahoo New Zealand News
SEC Form 424B5 filed by InflaRx N.V. - Quantisnow
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo New Zealand News
InflaRx (NASDAQ:IFRX) Receives “Buy” Rating from HC Wainwright - Defense World
InflaRx's ARDS drug selected for BARDA Phase 2 study - Investing.com India
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Iron Mountain executive sells over $547k in company stock By Investing.com - Investing.com UK
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed ... - WICZ
InflaRx's GOHIBIC (Vilobelimab) Selected for First - GlobeNewswire
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed ... - StockTitan
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):